PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
$1.31
-2.96%
$406.9M
No data for this timeframe.
Vol
Market Cap$406.9M
Cap SizeSmall Cap
Analyst ConsensusBuy (60%)
Inst. Holders50 funds
Inst. Value$193.9M
Inst. Activity11 buys / 2 sells
Insider Activity0B / 3S
Insider Net $-$149.6K
Reddit Sentiment43° Neutral
SEC Reports6
Press Releases1
Recent Activity
Jun 8, 2026
short_volume
Short Volume: PACB — 56.5% short (1.2M / 2.0M)
Short: 1,157,590 | Exempt: 52,249 | TRF Vol: 2,048,812 | Short Ratio: 56.5% | Off-exchange volume (d
Jun 4, 2026
SEC
Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive P
8-K — Impact 3/10
Jun 3, 2026
Insider
MOHR MARSHALL was granted 223,492 shares
Director
Jun 3, 2026
Insider
Smith Christopher M was granted 223,492 shares
Director
Jun 3, 2026
Insider
Valantine Hannah was granted 223,492 shares
Director
May 22, 2026
SEC
Pacific Biosciences of California, Inc. (PACB) filed additional definitive proxy soliciting materials (DEFA14A) on May 2
DEFA14A — Impact 3/10
Apr 16, 2026
SEC
PacBio announced a date for its Q1 2026 earnings call but did not release financial results or provide updated guidance.
PRESS-RELEASE — Impact 3/10
Inst.
Nuveen, LLC — DOUBLED
2,950,929 shares ($3.9M)
Price Targets
$2.46
+87.7% upside
Strong Buy
Current $1.31
Low $1.50
Median $2.63
High $3.00
6 analysts
$1.50
$3.00
Analyst Ratings
4Strong Buy
5Buy
5Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Apr 14, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Mar 6, 2026 | Barclays | DOWNGRADE | Equal-Weight → Underweight |
| Dec 15, 2025 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▼ -1.7% | $-0.14 — $-0.12 | 2% YoY | 5 |
| Next Q | $-0.13 ▼ -2.6% | $-0.13 — $-0.12 | -5% YoY | 5 |
| Current FY | $-0.51 | $-0.52 — $-0.49 | 5% YoY | 5 |
| Next FY | $-0.40 ▲ +5.0% | $-0.48 — $-0.23 | 22% YoY | 5 |
Latest Reports
NEUTRAL
8-K
3/10
Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive P
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
Pacific Biosciences of California, Inc. (PACB) filed additional definitive proxy soliciting materials (DEFA14A) on May 2
May 22, 2026
NEUTRAL
Press
3/10
PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ARK Investment Management LLC | $47.9M | — |
| BlackRock, Inc. | $33.4M | — |
| SOFTBANK GROUP CORP. | $27.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.9M | — |
| Sumitomo Mitsui Trust Group, | $9.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | MOHR MARSHALL | A | $0.00 |
| Jun 3, 2026 | Smith Christopher | A | $0.00 |
| Jun 3, 2026 | Valantine Hannah | A | $0.00 |
| Jun 3, 2026 | LIVINGSTON RANDALL | A | $0.00 |
| Jun 3, 2026 | MILLIGAN JOHN | A | $0.00 |
Reddit Sentiment
43°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $193.9M total value (146,736,180 shares) as of 2026-Q1. Top holders: ARK, BlackRock,, SOFTBANK. Net buying activity: 11 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 36,273,288 | $47.9M | 24.7% | — |
| 2 | BlackRock, Inc. | 25,267,429 | $33.4M | 17.2% | — |
| 3 | SOFTBANK GROUP CORP. | 20,451,570 | $27.0M | 13.9% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 12,777,449 | $16.9M | 8.7% | — |
| 5 | Sumitomo Mitsui Trust Group, Inc. | 7,037,987 | $9.3M | 4.8% | — |
| 6 | STATE STREET CORP | 6,121,716 | $8.1M | 4.2% | — |
| 7 | D. E. Shaw & Co., Inc. | 3,637,547 | $4.8M | 2.5% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 3,509,613 | $4.6M | 2.4% | DOUBLED +616.1% |
| 9 | Nuveen, LLC | 2,950,929 | $3.9M | 2.0% | DOUBLED +247.9% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,868,393 | $3.8M | 2.0% | — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 2,489,100 | $3.3M | 1.7% | TRIM -35.4% |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,405,496 | $3.2M | 1.6% | — |
| 13 | VANGUARD FIDUCIARY TRUST CO | 1,986,483 | $2.6M | 1.4% | — |
| 14 | MORGAN STANLEY | 1,840,461 | $2.4M | 1.3% | DOUBLED +434.2% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,719,165 | $2.3M | 1.2% | — |
| 16 | BANK OF AMERICA CORP /DE/ | 1,666,706 | $2.2M | 1.1% | ADD +25.9% |
| 17 | CITADEL ADVISORS LLC | 1,576,051 | $2.1M | 1.1% | — |
| 18 | Invesco Ltd. | 1,468,148 | $1.9M | 1.0% | ADD +29.5% |
| 19 | GOLDMAN SACHS GROUP INC | 988,467 | $1.3M | 0.7% | — |
| 20 | DIMENSIONAL FUND ADVISORS LP | 899,550 | $1.2M | 0.6% | DOUBLED +177.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | DOUBLED | 848,219 | 2,950,929 | +247.9% | $3.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,850,600 | 2,489,100 | -35.4% | $3.3M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 323,749 | 899,550 | +177.9% | $1.2M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 23,900 | 469,875 | +1866.0% | $620.2K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 2,957,400 | 285,700 | -90.3% | $377.1K | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 52,708 | 248,477 | +371.4% | $326.8K | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 104,621 | 148,961 | +42.4% | $196.6K | 2026-Q1 |
| CWM, LLC | DOUBLED | 6,203 | 53,794 | +767.2% | $71.0K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 19,337 | 43,661 | +125.8% | $58.5K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 22,737 | 43,487 | +91.3% | $57.4K | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 21,435 | 30,941 | +44.3% | $40.8K | 2026-Q1 |
| Allworth Financial LP | ADD | 4,051 | 7,928 | +95.7% | $10.5K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,246 | 5,198 | +317.2% | $6.9K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 401,766 | 2,877,184 | +616.1% | $5.4M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 451,215 | 2,410,540 | +434.2% | $4.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,472,690 | 1,854,814 | +25.9% | $3.5M | 2025-Q4 |
| Invesco Ltd. | ADD | 1,106,773 | 1,433,011 | +29.5% | $2.7M | 2025-Q4 |
| Nuveen, LLC | DOUBLED | 270,184 | 848,219 | +213.9% | $1.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 231,955 | 314,014 | +35.4% | $587.2K | 2025-Q4 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 140,968 | 104,621 | -25.8% | $195.6K | 2025-Q4 |
| STIFEL FINANCIAL CORP | ADD | 54,709 | 70,860 | +29.5% | $132.5K | 2025-Q4 |
| Mariner, LLC | DOUBLED | 11,396 | 40,004 | +251.0% | $74.8K | 2025-Q4 |
| Wealthfront Advisers LLC | TRIM | 90,205 | 38,041 | -57.8% | $71.1K | 2025-Q4 |
| FMR LLC | ADD | 18,576 | 29,855 | +60.7% | $55.8K | 2025-Q4 |
| Atria Investments, Inc | ADD | 21,761 | 27,496 | +26.4% | $51.4K | 2025-Q4 |
12 unique insiders with 23 transactions. Net insider value: -$149.6K ($0.00 bought, $149.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | MOHR MARSHALL | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | Smith Christopher M | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | Valantine Hannah | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | LIVINGSTON RANDALL S | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | MILLIGAN JOHN F | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | Gibson Christopher | Director | AWARD | 74,497 | — | — |
| Jun 3, 2026 | Ericson William W. | Director | AWARD | 223,492 | — | — |
| Jun 3, 2026 | ORDONEZ KATHY | Director | AWARD | 223,492 | — | — |
| Apr 8, 2026 | Gibson Christopher | Director | AWARD | 57,473 | — | — |
| Apr 8, 2026 | Gibson Christopher | Director | AWARD | 77,842 | — | — |
| Apr 1, 2026 | Gibson James R II | See Remarks | SELL | 88,185 | $1.37 | $120.8K |
| Mar 3, 2026 | Van Oene Mark | See Remarks | SELL | 6,504 | $1.51 | $9.8K |
| Mar 3, 2026 | Gibson Christopher | Director | AWARD | 53,913 | — | — |
| Mar 3, 2026 | HENRY CHRISTIAN O | See Remarks | SELL | 12,497 | $1.51 | $18.9K |
| Mar 3, 2026 | Gibson Christopher | Director | AWARD | 73,087 | — | — |
| Feb 27, 2026 | Gibson James R II | See Remarks | AWARD | 333,848 | — | — |
| Feb 27, 2026 | Van Oene Mark | See Remarks | AWARD | 500,000 | — | — |
| Feb 27, 2026 | Farmer Michele | See Remarks | AWARD | 89,835 | — | — |
| Feb 27, 2026 | Gibson James R II | See Remarks | AWARD | 667,696 | — | — |
| Feb 27, 2026 | Van Oene Mark | See Remarks | AWARD | 1,000,000 | — | — |
| Feb 27, 2026 | HENRY CHRISTIAN O | See Remarks | AWARD | 920,810 | — | — |
| Feb 27, 2026 | HENRY CHRISTIAN O | See Remarks | AWARD | 1,841,621 | — | — |
| Feb 27, 2026 | Farmer Michele | See Remarks | AWARD | 179,670 | — | — |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
3/10
Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 202
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
Pacific Biosciences of California, Inc. (PACB) filed additional definitive proxy soliciting material
May 22, 2026
NEUTRAL
PRESS-RELEASE
3/10
PacBio announced a date for its Q1 2026 earnings call but did not release financial results or provi
Apr 16, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Pacific Biosciences of California (PACB) over the past week con
Mar 5, 2026
NEUTRAL
8-K
3/10
Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and T
Mar 5, 2026
BULLISH
INST-CLUSTER
7/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
Current analyst consensus: Buy (60% buy). Based on 15 analysts: 4 strong buy, 5 buy, 5 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$2.46 mean target
+87.7% upside
Strong Buy (2.00)
$1.50 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $1.31 |
| Target Low | $1.50 |
| Target Mean | $2.46 |
| Target Median | $2.63 |
| Target High | $3.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.14 | $-0.12 | 2.5% | -1.7% | 2↑ 1↓ | $0.0B | 2.3% | 5 |
| Next Q 2026-09-30 |
$-0.13 | $-0.13 | $-0.12 | -5.3% | -2.6% | 1↑ 2↓ | $0.0B | 12.2% | 5 |
| Current FY 2026-12-31 |
$-0.51 | $-0.52 | $-0.49 | 4.6% | +0.4% | 2↑ 1↓ | $0.2B | 4.9% | 5 |
| Next FY 2027-12-31 |
$-0.40 | $-0.48 | $-0.23 | 21.6% | +5.0% | 3↑ 1↓ | $0.2B | 15.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.127 | |
| 7d ago | $-0.126 | -0.001 |
| 30d ago | $-0.125 | -0.002 |
| 60d ago | $-0.125 | -0.002 |
| 90d ago | $-0.127 | -0.000 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Apr 14, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Mar 6, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Dec 15, 2025 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 5 | 1 | 0 | 60% | |
| May 1, 2026 | 4 | 5 | 6 | 1 | 0 | 56% | |
| Apr 1, 2026 | 4 | 5 | 6 | 1 | 0 | 56% | |
| Mar 1, 2026 | 4 | 5 | 7 | 0 | 0 | 56% | |
| Feb 1, 2026 | 3 | 5 | 7 | 0 | 0 | 53% | |
| Jan 1, 2026 | 4 | 5 | 7 | 0 | 0 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
43°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
2 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 8, 2026
short_volume
Short Volume: PACB — 56.5% short (1.2M / 2.0M)
Short: 1,157,590 | Exempt: 52,249 | TRF Vol: 2,048,812 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 26, 2026
other
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methyl
May 21, 2026
other
PacBio to Participate in the Jefferies Global Healthcare Conference
<p>MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solut
May 20, 2026
short_volume
Short Volume: PACB — 62.1% short (1.2M / 1.9M)
Short: 1,151,511 | Exempt: 7,942 | TRF Vol: 1,855,087 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: PACB — 62.6% short (1.6M / 2.6M)
Short: 1,646,969 | Exempt: 9,202 | TRF Vol: 2,630,200 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: PACB — 72.6% short (3.7M / 5.2M)
Short: 3,743,098 | Exempt: 31,270 | TRF Vol: 5,155,038 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: PACB — 70.6% short (3.6M / 5.2M)
Short: 3,642,036 | Exempt: 13,251 | TRF Vol: 5,155,118 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: PACB — 57.1% short (2.2M / 3.9M)
Short: 2,234,719 | Exempt: 10,325 | TRF Vol: 3,915,802 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
fda
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking
May 8, 2026
short_volume
Short Volume: PACB — 58.8% short (2.7M / 4.7M)
Short: 2,736,771 | Exempt: 118,871 | TRF Vol: 4,654,854 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
PACB Q1 2026 Earnings After Market Close — 2026-05-07
Apr 29, 2026
short_volume
Short Volume: PACB — 65.6% short (2.1M / 3.2M)
Short: 2,121,912 | Exempt: 29,067 | TRF Vol: 3,234,556 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: PACB — 64.3% short (1.3M / 2.0M)
Short: 1,254,273 | Exempt: 13,351 | TRF Vol: 1,950,134 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: PACB — 66.1% short (2.2M / 3.3M)
Short: 2,162,313 | Exempt: 8,277 | TRF Vol: 3,269,560 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: PACB — 67.7% short (1.7M / 2.6M)
Short: 1,738,703 | Exempt: 1,521 | TRF Vol: 2,568,047 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)